Transform chemo-induced nausea and vomiting outcomes through transdermal patch technology
PRECAUTIONARY STATEMENT

This presentation, any supplemental information or documents provided herewith and any attendant oral commentary (collectively, this “Presentation”) (i) have been prepared for discussion purposes by ChemioCare (“ChemioCare”), (ii) are intended solely for use by ChemioCare’s in connection with the Company’s financial presentation dated as of the date hereof and (iii) should not be used, considered or relied upon for any other purpose or in connection with any other matter. With respect to any investment in the Company you should only rely on the materials presented in connection with such investment (the “Definitive Agreement”) and not on this Presentation. This Presentation will not be deemed to constitute financial advice or an offering of securities. This Presentation is confidential and proprietary and, without the prior written consent of ChemioCare, may not be reproduced, disseminated, quoted from or referred to, in whole or in part, at any time, in any manner or for any purpose. If you are not the intended recipient of this Presentation, please immediately delete and destroy all copies in your possession.

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for ChemioCare, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of ChemioCare. Any forward-looking statements which we make in this Presentation, represent our views only as of today. We disclaim any duty to update any such forward-looking statements. In addition, market data, such as but not limited to, our revenue potential or the size of a generic drug market is derived from third-party sources, and we have not verified the accuracy of such data.
• Compared to new molecular entity drug development, ChemioCare is: **Low Risk, Fast to Market**, with **Limited Capital Needs**

• Current treatment of CINV represents a **significant unmet medical need** and with multiple medicines being used that are associated with significant side effects

• ChemioCare uses **proprietary, proven transdermal patch technology**, to improve efficacy and reduce or eliminate side effects

• Multiple shots on goal: **four** single active ingredient patches in development with **numerous potential combinations** and **expansions** into other indications

• Revenue potential **up to $1B per patch** among 4+ patches

• Referencing well known, established generic medicines: efficacy, safety, and manufacturing are readily available

• Targeting 505(b)2 regulatory path with **key differentiators on-label** from originator products

**Transforming treatment of chemo-induced nausea and vomiting (CINV)**
MULTIPLE SHOTS ON GOAL: IMPROVED PROBABILITY OF SUCCESS

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Animal POC</th>
<th>Human POC</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHEMIO-ONDAN</td>
<td>IPO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHEMIO-DEX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHEMIO-OLANZ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHEMIO-DRON</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-INGREDIENT COMBOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTHER INDICATIONS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Low risk, accelerated go-to market via 505(b)2 regulatory pathway

6 potential combinations

Multiple opportunities to expand beyond CINV for each patch

Revenue potential up to $1B per patch

POC: Proof of Concept; Ondan: Ondansetron; Dex: Dexamethasone; Olanz: Olanzapine; Dron: Dronabinol
MOST ADVANCED PATCH: CHEMIO-ONDAN

Current shortcomings with IV and Oral ondansetron and other 5-HT3 formulations:

<table>
<thead>
<tr>
<th>Issue</th>
<th>Opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not indicated for High Risk Delayed CINV</td>
<td>Opportunity to be the First 5HT3 Receptor antagonist with an on label indication for Highly Emetogenic delayed CINV patients</td>
</tr>
<tr>
<td>Suboptimal level of protection</td>
<td>Breakthrough CINV symptoms in MEC, HEC, Acute AND Delayed</td>
</tr>
<tr>
<td>QT Elongation warning on label</td>
<td>Opportunity to avoid QT Elongation, a cardiac safety warning on the label for all 5-HT3s, through transdermal’s lower peak blood levels</td>
</tr>
</tbody>
</table>

Degree of superiority over 5-HT3 receptor antagonists will determine price & share

Revenue potential up to $1 Bn

CINV: Chemotherapy induced nausea and vomiting; MEC: Moderately emetogenic chemotherapy; HEC: Highly emetogenic chemotherapy
SIGNIFICANT OPPORTUNITIES FOR IMPROVEMENT IN CINV

Control under 2015 guidelines* □ Opportunity for improvement

<table>
<thead>
<tr>
<th></th>
<th>Complete Control (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEC Acute</td>
<td>94%</td>
</tr>
<tr>
<td>MEC Delayed</td>
<td>58% 42%</td>
</tr>
<tr>
<td>HEC Acute</td>
<td>77% 23%</td>
</tr>
<tr>
<td>HEC Delayed</td>
<td>41% 59%</td>
</tr>
</tbody>
</table>

Prescriber adherence to guidelines

- MEC Acute: 73%
- MEC Delayed: 99%
- HEC Acute: 91%
- HEC Delayed: 29%

* Excludes use of recent guideline addition olanzapine
3 sites included in prospective study included NK1 in MEC acute in protocol

Opportunity to improve efficacy, side effect profiles, adherence, and compliance

1. Novel **composition of matter** of ondansetron

2. **Method of use** of transdermal delivery for CINV, PONV, Radiology

3. Ondansetron transdermal patch achieving **fast delivery of therapeutic protection** (<1 hr) as well as a **sustained slow release for 5 days**

4. Achievement of **adequate sustained blood levels** of Ondansetron through a transdermal delivery system

5. **Formulation** patents

6. Transdermal Delivery of Dronabinol, 5-HT3 receptor antagonist and Dexamethasone alone or in combinations thereof

---

**Multiple patents eligible for listing in FDA Orange Book**

CINV: Chemotherapy induced nausea and vomiting, PONV: Postoperative nausea and vomiting
**CAPITAL STRUCTURE**

- Majority ownership by Founders
- Investor base is primarily Family Offices and High Net Worth Individuals
- Financial model validated by top-tier consultancy

**Pre-Money valuation:** $25.9 M

**Target raise:** $6.0 M

**Price per share:** $0.55

ChemioCare targeting NASDAQ + TSX dual-listing Q1/Q2 2019
MANAGEMENT AND BOARD

PEDRO LICHTINGER – CHAIRMAN & CEO
An industry executive with a 37-year career in biotechnology and a proven track record of developing turnaround and financing strategies, executing strategic alliances, and building commercial and R&D capabilities. President of Global Primary Care and President of Europe during 16 years at Pfizer. Former President and CEO of Asterias Biotherapeutics and Optimer Pharmaceuticals. Currently serves on Board of Directors for Gemphire Therapeutics and Sanfer de Mexico and sits on the Advisory Board of Zero Gravity.

CIDNEE VAYKOVICH – DIRECTOR OF OPERATIONS, DIRECTOR
Known for implementation in the biotech sector, she has spent most of her career creating and validating biotech companies. Previously in New Product Development at Aequus Pharmaceuticals, a transdermal reformulation company. Holds a Master of Management from the University of British Columbia and a Bachelor of Health Science and Biology from Western University.

JULIAN HOWELL – CHIEF MEDICAL ADVISOR
Broad experience in development of CINV products; including successful registration and launch of Sancuso® (granisetron patch) and Kytril® (granisetron oral). Clinical development experience spanning 15 years, bringing small molecules and biological products through all phases of clinical development including multiple product approvals in Europe and the US. He gained medical and surgical qualifications in the UK and worked in the UK health service before completing an MBA at Cranfield University and joining the pharmaceutical industry, initially at SmithKlineBeecham and subsequently in senior clinical and medical affairs roles at Roche, Chiron and Pharmion.

NITIN KAUSHAL - DIRECTOR
Managing Director, Corporate Finance, PwC Canada

FOTIOS PLAKOGIANNIS - DIRECTOR
Managing Director at Transdermal Research Pharm Laboratories

ROMAN ROGOL – DIRECTOR
Senior Partner and Portfolio Manager at Fairmont Capital